Home » USA Broker Ratings » ICON plc – Consenus Indicates Potential 28.0% Upside

ICON plc – Consenus Indicates Potential 28.0% Upside

ICON plc with ticker code (ICLR) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 203 and 131 with the average target price sitting at 175.07. Now with the previous closing price of 136.78 this now indicates there is a potential upside of 28.0%. The day 50 moving average is 154.39 and the 200 moving average now moves to 156.79. The market capitalisation for the company is $7,104m. Find out more information at: http://www.iconplc.com

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company’s clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Join us on our new LinkedIn page

Follow us on LinkedIn